Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results. The firm keeps a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: